Navigation Links
Neurobiological Technologies Reports Second Quarter Financial Results
Date:2/11/2008

eds. This will support our Phase 3 clinical trials for Viprinex(TM). We are pleased that the investors in this offering included existing shareholders, significant new institutional investors and members of our Board of Directors. We continue to invest in our key asset, Viprinex, for acute ischemic stroke currently in two Phase III clinical trials. We believe Viprinex has the potential to double the treatment window over the current approved drug, while at the same time reducing the major side effects of fibrinolytics, namely, symptomatic intracranial hemorrhage."

Freiman continued: "I am also very pleased Dr. Warren Wasiewski, who joined NTII in February 2007 as Vice President, Clinical Programs was promoted to Chief Medical Officer of NTII with primary responsibility for running the clinical trial program for Viprinex. Dr. Wasiewski is a Board Certified Pediatric Neurologist with an extensive clinical career. Prior to joining NTII, he worked at AstraZeneca where he was Sr. Medical Director of clinical research CNS/Emerging Products. At AstraZeneca, Dr. Wasiewski had responsibility for running the global SAINT trials for AstraZeneca's neuroprotectant drug candidate."

About Viprinex Phase 3 Trial Program

Viprinex is an investigational agent with multiple novel mechanisms of action that appear to have the potential to expand the treatment window for treating acute ischemic stroke with a lower risk of intracranial bleeding. The only approved agent to treat stroke is required to be given within the first three hours of stroke symptoms primarily due to increased bleeding risk beyond that window. This time limit has been a barrier to receiving care and improving outcomes and quality of life for stroke patients. Previous large Phase III trials have demonstrated that Viprinex may be effective and appears to be well tolerated for acute ischemic stroke.

Conference Call Information

NTI will webcast its quarterly financial results and host a
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Neurobiological Technologies Reports Going Concern Qualification
2. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
3. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
6. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
7. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
8. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
9. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. Advanced technologies aim to transform the coaching of top athletes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
(Date:3/28/2015)... Lately the student-athlete experience has ... proposals around the NCAA. In a March episode of ... across a spectrum of universities and sports shed light ... special panel consists of athletes who have competed for ... track and field, baseball, and volleyball. They discuss the ...
(Date:3/28/2015)... 28, 2015 The "Petrick Sustainable ... sustainable health. After 18 years of research and experience ... UFC contenders, Dr. Jon Petrick is excited to be ... some of the immediate benefits of this radical new ... levels of strength of the immune system, faster healing ...
(Date:3/28/2015)... Plainview, NY (PRWEB) March 28, 2015 ... provider of dietary supplements announces the release of ... MuffinStop™ was shown in two randomized, double-blind, placebo-controlled ... weight and waist and hip size. MuffinStop™ is ... Sphaeranthus indicus and Garcinia mangostana, fused together to ...
(Date:3/27/2015)... FL (PRWEB) March 27, 2015 The ... guide from dating experts Samantha Sanderson and Jason Rogers ... frenzied buzz of media attention. The commotion surrounding the ... Roman, prompting him to publish an in-depth review of ... devastated when the men in their lives suddenly start ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... Treuman Katz Center for Pediatric Bioethics at Seattle Children,s ... Conference on Friday, July 22 and Saturday, July 23. ... policy boundaries and complexities of providing healthcare to children. ... the Boundaries of Clinical Ethics and Public Policy," will ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... skin rashes, but the similarities between the two common, ... examining patients suffering from both ailments (a very rare ... system responses that prompt skin flare-ups for both diseases. ...
... , WEDNESDAY, July 20 (HealthDay News) -- The ... their patients, health, new research indicates. It also plays ... errors and patient satisfaction, according to a commentary in the ... who are civil, the report claimed, can more effectively help ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) ... be heating up. New technology promises to cut costs while ... of your genes and potentially provide a personalized report of ... The human genome was first mapped in 2001 and cost ...
... cascade of chemistry to stem the flow of blood. Now, ... have used evolutionary clues to reveal how a key clotting ... disorders. The long tube-shaped protein with a vital role ... in cells that form the inner lining of blood vessels, ...
... , In the fight to improve global health, alleviate ... developing world, chickens have an important role to play. ... Center for Infectious Diseases and Vaccinology at Arizona State ... a more productive species of chicken for villagers in ...
Cached Medicine News:Health News:Exploring the limits of children's health care: What's the reality of providing care to all? 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 3Health News:Rude Surgeons Hurt Patients, Increase Costs 2Health News:Cheaper DNA Sequencing Coming Closer 2Health News:Cheaper DNA Sequencing Coming Closer 3Health News:Evolution provides clue to blood clotting 2Health News:Evolution provides clue to blood clotting 3Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 2Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 3
(Date:3/27/2015)... LAVAL, Quebec , March 27, 2015  Valeant ... announced today the closing of its previously announced registered ... States (the "Offering"). Pursuant to the Offering, ... of $199.00 per share, for aggregate gross proceeds of ... filed with the U.S. Securities and Exchange Commission a ...
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... reporting of data from a single -center experience ... the Delcath Hepatic Delivery System (Melphalan/HDS) and other ... of Surgical Oncology (SSO) Annual Meeting 2015.  The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: